SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 33,900 shares, an increase of 50.7% from the May 15th total of 22,500 shares. Based on an average daily volume of 17,400 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.5% of the company’s shares are short sold.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday, May 21st. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday, May 21st. Finally, Brookline Capital Management started coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They issued a “buy” rating and a $8.00 target price for the company.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds have recently made changes to their positions in the stock. Pathstone Family Office LLC bought a new position in SAB Biotherapeutics during the 3rd quarter valued at $319,000. RTW Investments LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $6,310,000. BVF Inc. IL acquired a new position in SAB Biotherapeutics in the fourth quarter worth about $6,310,000. Finally, Commodore Capital LP bought a new stake in SAB Biotherapeutics in the fourth quarter valued at about $1,259,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 2.5 %

SABS stock traded down $0.08 during trading on Friday, reaching $3.15. The stock had a trading volume of 10,111 shares, compared to its average volume of 35,925. The firm has a fifty day moving average price of $3.70 and a 200 day moving average price of $3.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.65 and a current ratio of 5.65. SAB Biotherapeutics has a 1-year low of $2.36 and a 1-year high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Monday, May 20th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.44. SAB Biotherapeutics had a negative return on equity of 109.90% and a negative net margin of 1,531.26%. The firm had revenue of $0.95 million during the quarter. As a group, sell-side analysts expect that SAB Biotherapeutics will post -4.08 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.